Show simple item record

dc.contributor.authorLind, Guro Elisabethen_US
dc.contributor.authorGuriby, Marianneen_US
dc.contributor.authorAhlquist, Terje Cruickshanken_US
dc.contributor.authorHussain, Israren_US
dc.contributor.authorJeanmougin, Marineen_US
dc.contributor.authorSøreide, Kjetilen_US
dc.contributor.authorKørner, Hartwigen_US
dc.contributor.authorLothe, Ragnhild Aen_US
dc.contributor.authorNordgård, Oddmunden_US
dc.PublishedLind GE, Guriby M, Ahlquist TC, Hussain I, Jeanmougin M, Søreide K, Kørner H, Lothe RA, Nordgård O. Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients. Clinical Epigenetics. 2017;9:97eng
dc.description.abstractBackground: Patients with early colorectal cancer (stages I–II) generally have a good prognosis, but a subgroup of 15–20% experiences relapse and eventually die of disease. Occult metastases have been suggested as a marker for increased risk of recurrence in patients with node-negative disease. Using a previously identified, highly accurate epigenetic biomarker panel for early detection of colorectal tumors, we aimed at evaluating the prognostic value of occult metastases in sentinel lymph nodes of colon cancer patients. Results: The biomarker panel was analyzed by quantitative methylation-specific PCR in primary tumors and 783 sentinel lymph nodes from 201 patients. The panel status in sentinel lymph nodes showed a strong association with lymph node stage (P = 8.2E−17). Compared with routine lymph node diagnostics, the biomarker panel had a sensitivity of 79% (31/39). Interestingly, among 162 patients with negative lymph nodes from routine diagnostics, 13 (8%) were positive for the biomarker panel. Colon cancer patients with high sentinel lymph node methylation had an inferior prognosis (5-year overall survival P = 3.0E−4; time to recurrence P = 3.1E−4), although not significant. The same trend was observed in multivariate analyses (P = 1.4E−1 and P = 6.7E−2, respectively). Occult sentinel lymph node metastases were not detected in early stage (I–II) colon cancer patients who experienced relapse. Conclusions: Colon cancer patients with high sentinel lymph node methylation of the analyzed epigenetic biomarker panel had an inferior prognosis, although not significant in multivariate analyses. Occult metastases in TNM stage II patients that experienced relapse were not detected.en_US
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BYeng
dc.subjectDNA methylationeng
dc.subjectOccult metastaseseng
dc.subjectSentinel lymph nodeseng
dc.titlePrognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patientsen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2017 The Author(s)
dc.source.journalClinical Epigenetics
dc.relation.projectNorges forskningsråd: 179571

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY